Chemical Reprogramming of Non-Cardiac Cells to Cardiomyocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell reprogramming methods for converting differentiated cells into cardiac lineage are inefficient and require genetic manipulation, raising concerns about introduced mutations.
Innovation Solution
A composition of chemical agents including WNT agonists, GSK3 inhibitors, TGF-beta inhibitors, ERK1 inhibitors, Oct-4 activators, and other specific compounds is used to reprogram differentiated cells into cardiac progenitor cells and cardiomyocytes without genetic engineering, utilizing a combination of agents such as CHIR99021, A83-01, SC1, OAC2, Y27632, BIX-01294, AS8351, and JNJ-10198409.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic manipulation methods are used to reprogram cells, then cell reprogramming can be achieved, but introduced mutations may occur
Solution Approach 1:
The patent replaces genetic manipulation methods with chemical small molecule treatments to achieve cell reprogramming. Instead of using viral vectors or transgenic techniques that introduce foreign DNA and risk mutations, the invention uses small molecules to modulate signaling pathways and gene expression, thereby eliminating the harmful effect of introduced mutations while maintaining reprogramming efficacy.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries to mediate the reprogramming process. These small molecules act as temporary, reversible modulators of cellular signaling pathways rather than permanent genetic changes. The small molecules serve as safe intermediaries that can be added and removed without leaving permanent genetic alterations in the target cells.
2Reliability
If traditional reprogramming methods are used, then cell conversion can occur, but reprogramming efficiency is low
Solution Approach 1:
The patent systematically optimizes multiple parameters including small molecule concentrations, treatment durations, and combination regimens to maximize reprogramming efficiency. By adjusting these parameters, the invention achieves significantly higher conversion rates compared to traditional methods, transforming an inefficient process into a highly productive one while maintaining cell conversion capability.
Solution Approach 2:
The patent employs composite treatment regimens combining multiple small molecules that target different signaling pathways simultaneously. This multi-component approach creates synergistic effects that enhance reprogramming efficiency beyond what single agents can achieve, effectively using a composite strategy to overcome the limitations of traditional single-factor reprogramming methods.
Data Source
AI summary
Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become cardiac progenitor cells or cardiomyocytes.